跳至主要内容
临床试验/NCT02215343
NCT02215343已完成不适用

Effect of Prebiotic Fibre and Polyunsaturated Fatty Acid (PUFA) on the Gut Microbiota and Metabolic Risk Markers in a Metabolically Challenged Population

University of Copenhagen2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2014年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
2
主要终点
Change in gut microbiota composition

研究概览

简要总结

The main objective of this study is to investigate in detail how a high-(prebiotic)fibre diet and a high-PUFA diet affect the gut microbiota composition in a metabolic challenged population, and if the diet-induced modulation of the gut microbiota mediates changes in metabolic risk markers.

Intake of both experimental diets over 4 weeks are expected to induce beneficial changes in the gut microbiota composition and to affect markers for insulin sensitivity, lipid metabolism and inflammation. The investigators hypothesize that the effect of both interventions on the metabolic risk markers will be partly mediated by the diet-induced changes in the gut microbiota composition.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • BMI: 25-40 kg/m2
  • Non-smoking
  • Indices of the Metabolic Syndrome defined by the International Diabetes Federation (IDF 2006):
  • Central obesity (waist circumference; men: ≥94 cm and women: ≥80 cm) + any one of the following; raised triglyceride level (≥1.7 mmol/L), reduced HDL cholesterol (men: <1.03 mmol/L, women: <1.29 mmol/L), raised BP (systolic ≥130 mm Hg or diastolic ≥85 mm Hg) or raised fasting plasma glucose (≥5.6 mmol/L).

排除标准

  • Use of antibiotics
  • Weight change >3 kg 2 months prior to study start
  • Intensive physical training/ elite athlete
  • Medication for dyslipidemia, type 2 diabetes or elevated blood pressure
  • Dietary supplements with pro/prebiotics, dietary fibre or fish oil supplement
  • Lactation, pregnancy or planning of pregnancy during the study
  • Gastro intestinal and liver disorders
  • Chronic inflammatory disorders
  • Diagnosed psychiatric disorder including treatment required depression
  • Surgical treatment of obesity and abdominal surgery

结局指标

主要结局

Change in gut microbiota composition

时间窗: Week 0, 4, 8, 12

Gut microbiota composition will be analyzed by use of fecal samples.

次要结局

  • Faecal SCFA and bile acid composition(Week 0, 4, 8, 12)
  • Change in markers for lipid metabolism(Week 0, 4, 8, 12)
  • Change in markers for insulin sensitivity(Week 0, 4, 8, 12)
  • Change in markers for inflammation(Week 0, 4, 8, 12)
  • Lipidomics(Week 0, 4, 8, 12)
  • Metabolomics(Week 0, 4, 8, 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Arne Astrup

Professor, Dr.Med.

University of Copenhagen

研究点 (2)

Loading locations...

相似试验